Authors
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Cancer Pain and Opioid Use DisorderInvestigators support individualized approaches and compassionate care to minimize nonmedical opioid use and opioid use disorder in patients with cancer pain.
Latest:
Lisa La on the Limitations of a Study Evaluating Diabetes in Patients with Multiple MyelomaThe clinical investigator and her colleagues sought to evaluate differences in baseline characteristics, treatment patterns, and survival outcomes in diabetic versus nondiabetic patients enrolled in the CONNECT Multiple Myeloma Registry.
Latest:
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell CarcinomaIn this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.
Latest:
Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a CarcinosarcomaOn this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.
Latest:
Reid Merryman, MD, on Potential Clinical Designs with MRD-Guidance for Patients with DLBCLExpert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.
Latest:
Metastatic CRC: Unmet Needs and Future Directions in CareClosing out their review of the metastatic colorectal cancer treatment paradigm, expert panelists consider how the treatment armamentarium will continue to evolve.
Latest:
Managing Hematological Toxicities Associated with Bispecifics in MMExperts on multiple myeloma provide insights on the management of hematological toxicities associated with bispecific antibodies.
Latest:
Addition of Sintilimab to Bevacizumab Biosimilar IBI305 and Chemo Boosts PFS vs Chemo in Advanced EGFR-Mutant NSCLCPatients with locally advanced or metastatic EGFR-mutant nonsquamous non–small cell lung cancer who progressed on an EGFR inhibitor may benefit from treatment with sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy vs chemotherapy alone.
Latest:
Integrative Oncology in Young Women With Breast CancerYancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Latest:
Preferred Treatment of RAS Wild-Type, BRAF V600E Mutant mCRC Favors Bevacizumab Over CetuximabCertain patients with RAS wild-type colorectal cancer should be treated with bevacizumab in place of cetuximab in combination with FOLFOXIRI.
Latest:
Current Treatment of Peripheral T-cell LymphomaThis review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.
Latest:
Advanced Bladder Cancer: Future Directions in CareClosing out their panel on advanced bladder cancer management, key opinion leaders share their excitement for future evolutions within the treatment landscape.
Latest:
Molecular Profiling in Metastatic Colorectal CancerABSTRACT: Colorectal cancer (CRC) is a commonly diagnosed malignancy. Although chemotherapy remains the backbone of treatment, the landscape of treating metastatic CRC (mCRC) is changing with the understanding of its heterogeneity and molecular blueprint. Colon cancer sidedness has proven to hold prognostic implications, with right-sided tumors having higher incidence of BRAF and KRAS mutations and being microsatellite instability–high (MSI-H); overall, they have a worse prognosis compared with left sided-tumors. Results of molecular research have demonstrated the need to profile each mCRC patient for RAS and BRAF mutations, MSI-H status, HER2 amplifications, and NTRK fusions. Ongoing clinical trials using targeted agents aim to further improve survival outcomes. We emphasize the epidemiology, knowledge of primary tumor location, and mutational landscape of mCRC, as well as novel treatment options for patients harboring unique subtypes of these characteristics.
Latest:
Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research RecommendationsThis review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.
Latest:
Value of Geriatric Assessment in Patients With Genitourinary CarcinomaThis work from Quirin Zangl, MD, and colleagues to evaluate comprehensive geriatric assessment tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use.
Latest:
Current Treatment of Burkitt Lymphoma and High-Grade B-Cell LymphomasP. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma.
Latest:
Clinical Pearls on Recent Advances and the Future of Treatment in RCCMehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.
Latest:
Deepu Madduri, MD, on Research in Multiple Myeloma This Past YearThe expert in multiple myeloma spoke about the research that she believes will be most influential for patients with multiple myeloma.
Latest:
Data Confirm Dara-KRd/Double Transplant Benefit in Newly Diagnosed MyelomaInvestigators report a low rate of high-grade hematologic adverse effects following treatment with induction Dara-KRd and consolidation double transplant in patients with high-risk, newly diagnosed multiple myeloma.
Latest:
Unmet Needs and Future Perspectives in Multiple Myeloma TreatmentA look at the unmet needs and future directions of multiple myeloma treatment.
Latest:
Paolo Ghia, MD, PhD, on the Chemo-Free, All-Oral Regimen of Ibrutinib Plus Venetoclax for First-Line CLL at ASCO 2021Paolo Ghia, MD, PhD, discussed data from the CAPTIVATE trial of ibrutinib/venetoclax in the frontline setting for chronic lymphocytic leukemia.
Latest:
Many Factors Influence Selection of CAR T Therapy, Bispecifics in MyelomaBispecific antibodies may be more broadly applicable as treatment for patients with multiple myeloma in the short-term, according to Ajai Chari, MD.
